CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 185 enrolled
Drug / intervention
bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01217606
NCT01217606Phase 3Completed
CompareCT.gov

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Allergan·interventional·Posted Oct 8, 2010·Updated Dec 20, 2016

In Brief

A Phase 3 clinical trial evaluating bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy) and Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 185 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesBrazil
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 8, 2010
Enrollment StartJan 1, 2011
Primary CompletionSep 1, 2014
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 15.7 years ago

Interventions

bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)drug

One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.

Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solutiondrug

One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.